1887

Journal of Medical Microbiology logo

Volume 71, Issue 1

Comparison of sequential therapy with concomitant therapy in first-line treatment of : an updated meta-analysis No Access

Abstract

Sequential therapy (ST) and concomitant therapy (CT) are common first-line treatments for (HP). This study aimed to assess the efficiency and safety of ST and CT in the first-line treatment of HP by comparing their clinical outcomes. Two authors independently searched PubMed, EBSCO, Web of Science and the Cochrane Library for all the relevant articles published before March 2021 to compare the clinical outcomes of HP patients undergoing ST or CT. The primary outcome measures were HP eradication rates and adverse events (AEs). This meta-analysis included 24 articles with 7531 HP patients. CT was better than ST in eradicating HP from per-protocol analysis (PP) (RR=0.96, <0.001) and modified intent-to-treat analysis (MITT) (RR=0.94, =0.005). Compared with non-Asia, CT demonstrated more apparent advantages than ST in Asia. CT treated with lansoprazole, pantoprazole and esomeprazole outperformed ST treated with the same PPIs. CT for 10 days and ST for 14 days were the better choices of course of treatment. The incidence rates of AEs were significantly higher in CT than in ST for diarrhoea (RR=0.65, <0.001), vomiting (RR=0.68, =0.03), dysgeusia (RR=0.83, =0.03) and dizziness (RR=0.77, =0.05). Both ST and CT are safe and effective first-line treatments for HP. Although the AEs were more frequent with CT than ST, CT was superior to ST, especially in Asia. The effect of various PPIs varied in various therapies. The best course of treatment was 10 days for CT and 14 days for ST.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): concomitant therapy , eradication rates , Helicobacter pylori , meta-analysis and sequential therapy
© 2022 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001490
2022-01-18
2024-12-05
Loading full text...

Full text loading...

References

  1. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017; 153:420–429 [View Article]
     [Google Scholar]
  2. Mezmale L, Coelho LG, Bordin D, Leja M. Review: Epidemiology of Helicobacter pylori. Helicobacter 2020; 25 Suppl 1:e12734 [View Article] [PubMed]
     [Google Scholar]
  3. Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018; 23:e12475 [View Article]
     [Google Scholar]
  4. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP et al. The Toronto consensus for the treatment of Helicobacter pylori infection in ainfection in adults. Gastroenterology 2016; 151:51–69 [View Article]
     [Google Scholar]
  5. Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017; 66:6–30 [View Article]
     [Google Scholar]
  6. Rinaldi V, Winn S, Meddi P, Lionetti R et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14:715–718 [View Article] [PubMed]
     [Google Scholar]
  7. Shamseer L, Clarke M, Ghersi D, Liberati A et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement. Syst Rev 2015; 4:1 [View Article] [PubMed]
     [Google Scholar]
  8. Wang Y, Zhao R, Wang B, Zhao Q, Li Z et al. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018; 74:1–13 [View Article]
     [Google Scholar]
  9. Altman DG, Gøtzsche PC, Jüni P, Moher D et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928 [View Article] [PubMed]
     [Google Scholar]
  10. Ang TL, Fock KM, Song M, Ang D, Kwek ABE et al. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection. J Gastroenterol Hepatol 2015; 30:1134–1139 [View Article]
     [Google Scholar]
  11. Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, Dogantzis P, Vlachou E et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol 2016; 51:145–151 [View Article]
     [Google Scholar]
  12. Chung J-W, Han JP, Kim KO, Kim SY, Hong SJ et al. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. Dig Liver Dis 2016; 48:888–892 [View Article]
     [Google Scholar]
  13. Das RR, Sureshkumar SS, Sreenath GS, Kate VV. Sequential versus concomitant therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer: A randomized trial. Saudi J Gastroenterol 2016; 22:309–315 [View Article]
     [Google Scholar]
  14. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014; 63:748–752 [View Article]
     [Google Scholar]
  15. De Francesco V, Pontone S, Bellesia A, Serviddio G, Panetta C et al. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study. Dig Liver Dis 2018; 50:139–141 [View Article]
     [Google Scholar]
  16. Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143:55–61 [View Article]
     [Google Scholar]
  17. Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, Zampeli E, Grivas E et al. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. Eur J Intern Med 2016; 32:84–90 [View Article] [PubMed]
     [Google Scholar]
  18. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507–514 [View Article]
     [Google Scholar]
  19. Gungor G, Baglıcakoglu M, Kayacetin E, Biyik M, Ucar R et al. Current status of five different regimens for empiric first-line Helicobacter pylori eradication in Turkey. Digestion 2015; 92:55–59 [View Article]
     [Google Scholar]
  20. Hsu P-I, Wu D-C, Chen W-C, Tseng H-H, Yu H-C et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother 2014; 58:5936–5942 [View Article]
     [Google Scholar]
  21. Huang Y-K, Wu M-C, Wang SS, Kuo C-H, Lee Y-C et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis 2012; 13:232–238 [View Article] [PubMed]
     [Google Scholar]
  22. Kefeli A, Basyigit S, Yeniova AO, Kefeli TT, Aslan M et al. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. Bosn J Basic Med Sci 2016; 16:52–57 [View Article] [PubMed]
     [Google Scholar]
  23. Kim BJ, Lee H, Lee YC, Jeon SW, Kim GH et al. Ten-day concomitant, 10-day sequential, and 7-day triple therapy as first-line treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver 2019; 13:531–540 [View Article]
     [Google Scholar]
  24. Kim SY, Lee SW, Choe JW, Jung SW, Hyun JJ et al. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter 2017; 22:e12441 [View Article]
     [Google Scholar]
  25. Lee HJ, Kim JI, Lee JS, Jun EJ, Oh J-H et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015; 21:351–359 [View Article] [PubMed]
     [Google Scholar]
  26. Lim JH, Lee DH, Choi C, Lee ST, Kim N et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 2013; 18:180–186 [View Article] [PubMed]
     [Google Scholar]
  27. McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63:244–249 [View Article] [PubMed]
     [Google Scholar]
  28. Myint N, Zaw TT, Sain K, Waiyan S, Danta M et al. Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability. J Gastroenterol Hepatol 2020; 35:617–623 [View Article]
     [Google Scholar]
  29. Park SM, Kim JS, Kim B-W, Ji J-S, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol 2017; 32:589–594 [View Article] [PubMed]
     [Google Scholar]
  30. Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A et al. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2016; 28:676–683 [View Article] [PubMed]
     [Google Scholar]
  31. Wu D-C, Hsu P-I, Wu J-Y, Opekun AR, Kuo C-H et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010; 8:36–41 [View Article] [PubMed]
     [Google Scholar]
  32. Zeriouh M, Elmekkaoui A, Bouqfar M, Zazour A, Khannoussi W et al. Non-bismuth quadruple therapy, sequential therapy or high-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a prospective randomized study. Cureus 2020; 12:e11837 [View Article] [PubMed]
     [Google Scholar]
  33. Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D’Ambrosio P et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37:647–650 [View Article]
     [Google Scholar]
  34. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1:1273–1275 [PubMed]
     [Google Scholar]
  35. Sgouras D, Tegtmeyer N, Wessler S. Activity and functional importance of Helicobacter pylori virulence factors. Adv Exp Med Biol 2019; 1149:35–56 [View Article]
     [Google Scholar]
  36. Gisbert JP, Calvet X. Helicobacter Pylori “Test-and-Treat” strategy for management of dyspepsia: a comprehensive review. Clin Transl Gastroenterol 2013; 4:e32 [View Article]
     [Google Scholar]
  37. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112:212–239 [View Article]
     [Google Scholar]
  38. Bae HJ, Kim JS, Kim BW, Nam YJ. Concomitant or sequential therapy as the first-line therapy for eradication of Helicobacter pylori infection in korea: a systematic review and meta-analysis. Korean J Gastroenterol 2018; 71:31–37 [View Article] [PubMed]
     [Google Scholar]
  39. Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A et al. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis. Gastroenterology 2021; 161:495–507 [View Article]
     [Google Scholar]
  40. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015; 54:703–710 [View Article]
     [Google Scholar]
  41. Kim JS, Park SM, Kim B-W. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2015; 30:1338–1345 [View Article] [PubMed]
     [Google Scholar]
  42. Song Z-Q, Zhou L-Y. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis. World J Gastroenterol 2016; 22:4766–4775 [View Article] [PubMed]
     [Google Scholar]
  43. Kuo C-H, Lu C-Y, Shih H-Y, Liu C-J, Wu M-C et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014; 20:16029–16036 [View Article]
     [Google Scholar]
  44. Dickey W, Kenny BD, McConnell JB. Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. Aliment Pharmacol Ther 1996; 10:289–293 [View Article]
     [Google Scholar]
  45. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8:888–889 [View Article]
     [Google Scholar]
  46. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idström JP et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111:358–367 [View Article]
     [Google Scholar]
  47. Scott DR, Weeks D, Hong C, Postius S, Melchers K et al. The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 1998; 114:58–70 [View Article]
     [Google Scholar]
  48. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998; 43 Suppl 1:S56–60 [View Article] [PubMed]
     [Google Scholar]
  49. Zhang H-J, Zhang X-H, Liu J, Sun L-N, Shen Y-W et al. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacol Res 2020; 152:104606 [View Article]
     [Google Scholar]
  50. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65:19–31 [View Article] [PubMed]
     [Google Scholar]
  51. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A et al. Influence of cyp2c19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20:153–167 [View Article] [PubMed]
     [Google Scholar]
  52. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22:266–280 [View Article] [PubMed]
     [Google Scholar]
  53. Abed MN, Alassaf FA, Jasim MHM, Alfahad M, Qazzaz ME. Comparison of antioxidant effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole. Pharmacology 2020; 105:645–651 [View Article]
     [Google Scholar]
  54. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008; 3:563–578 [View Article] [PubMed]
     [Google Scholar]
  55. Andersson KE. Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. Scand J Infect Dis Suppl 1981; 26:60–67 [PubMed]
     [Google Scholar]
  56. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf 2013; 12:497–505 [View Article] [PubMed]
     [Google Scholar]
  57. Novotny M, Klimova B, Valis M. Ppi long term use: risk of neurological adverse events?. Front Neurol 2018; 9:1142 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001490
Loading
Comparison of sequential therapy with concomitant therapy in first-line treatment of Helicobacter pylori: an updated meta-analysis
J. Med. Microbiol. 71, 001490 (2022); https://doi.org/10.1099/jmm.0.001490
/content/journal/jmm/10.1099/jmm.0.001490
/content/journal/jmm/10.1099/jmm.0.001490
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error